IP Library Granted Patent US 10,201,570
Granted Patent B2
US 10,201,570 · App. 15/117,602 · Granted Feb 12, 2019

Halogen treatment of heart attack and ischemic injury

Inventors: Mark B. Roth (Seattle, WA); Michael L. Morrison (Seattle, WA); Akiko Iwata (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center
A61K33/18A61K9/0053A61K33/00A61K33/04A61K33/16A61K38/063Y02A50/481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,570
App. No.
15/117,602
Granted
Feb 12, 2019
Kind
B2
Abstract

The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

Claims (8)

1. A method for treating or inhibiting a reperfusion injury resulting from restoration of blood flow to an ischemic tissue or organ in a subject, comprising providing to said subject a pharmaceutical composition comprising sodium iodide and a pharmaceutically acceptable carrier, diluent, or excipient, wherein said composition is provided to the subject in an amount sufficient to increase the blood concentration of iodide in the subject by at least 500% for at least some time.

2. The method of claim 1 , wherein said composition is provided to the subject parenterally.

3. The method of claim 2 , wherein said composition is provided to the subject intravenously.

4. The method of claim 1 , wherein said reperfusion injury occurs following percutaneous coronary intervention or thrombolysis.

5. The method of claim 1 , wherein the subject is provided with the pharmaceutical composition daily, twice daily, or once every two days.

6. The method of claim 5 , wherein the subject is provided with a dose of about 0.1 mg/kg to about 5 mg/kg of the sodium iodide.

7. The method of claim 6 , wherein the subject is provided with a dose of about 0.5 mg/kg to about 2 mg/kg of the sodium iodide.

8. The method of claim 7 , wherein the subject is provided with a dose of about 1.0 mg/kg of the sodium iodide.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded May 23, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: SEATTLE CANCER CARE ALLIANCE
Reel/Frame 060163/0887 →
CHANGE OF NAME Recorded May 23, 2022
From: SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060389/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2017
From: ROTH, MARK B.; MORRISON, MICHAEL L.; IWATA, AKIKO
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 041371/0196 →
Continuity (5)
Provisional Application 62082957 · Nov 21, 2014
Provisional Application 62060338 · Oct 6, 2014
Provisional Application 62007015 · Jun 3, 2014
Provisional Application 61937943 · Feb 10, 2014
Related Publication 20160346323A1 · Dec 1, 2016